Key Takeaways STE's Healthcare unit saw 6% organic growth, fueled by U.S. procedures, pricing and market share gains. STERIS' AST business saw robust growth, aided by EO sterilization and demand from biopharma makers. STE cut long-term debt by 38.5%, ending fiscal Q4 with more cash than short-term debt on the books.STERIS plc’s (STE) Healthcare segment is gaining from the successful market adoption of its comprehensive offering, including infection prevention consumables and capital equipment. The Applied ...

Investor Presentation June 2025 Forward Looking Statements This presentation contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward- looking statements speak only as to the date the statemen ...

STERIS' (STE) new acquisitions and partnerships strengthen its product offerings. The stock carries a Zacks Rank #2 (Buy) currently.Factors Driving STERIS' GrowthSTERIS’ Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to maintain that equipment, repair reusable procedural instruments and outsource instrument reprocessing services are gaining traction. For the fourth quart ...

STERIS plc’s (STE) Healthcare business continues to benefit from robust U.S. procedure volumes, favorable pricing and market share gains. Service revenues fuel the Applied Sterilization Technologies (“AST”) segment’s growth. Moreover, sound financial health bodes well for the stock. Meanwhile, macroeconomic challenges and adverse currency impacts appear concerning for the company’s operations. In the past year, shares of this Zacks Rank #3 (Hold) company have advanced 10.4% against the industry’s 10.4% fall ...